Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.
Video content above is prompted by the following:
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More